Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: Results and Patient Assessment
|
|
- Beatrice King
- 6 years ago
- Views:
Transcription
1 Original Paper Dermatology 206;232: Received: December 6, 205 Accepted after revision: August 3, 206 Published online: November 25, 206 Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: Results and Patient Assessment Montserrat Fernández-Guarino Sonsoles Aboín-González Diana Velázquez Lucia Barchino Natividad Cano Pablo Lázaro Department of Dermatology, Hospital Universitario Sanitas La Zarzuela, Madrid, Spain Key Words Psoriasis Phototherapy Narrow-band UVB Treatment Abstract Background: Acute guttate psoriasis (AGP) is a distinctive clinical entity with good response to treatment with narrowband ultraviolet B (NB-UVB). Objective: To investigate the results of NB-UVB phototherapy in adult patients with adult guttate psoriasis. Material and Methods: We carried out a prospective, open, and observational study. Patients over 8 years with more than 5% of body surface area affected were included. The PASI was assessed prior to and after treatment. The follow-up period was 8 months. After treatment, patients completed a simple questionnaire to assess their overall impression of the treatment. Results: The 67 adult patients with AGP included in this study had an initial PASI of 8.55 (SD 5.03). Patients were treated with a mean of 9.9 sessions (SD 3.5) and mean doses of 4 mj/cm 2 (SD 0.5). Of the 67 patients, 52 achieved PASI90 with 96.5% of PASI reduction, and of these, 46 (88%) maintained PASI90 during the 8 months of follow-up. Patients were very satisfied with the treatment. Discussion: AGP is a defined clinical entity with a variable course. Phototherapy with NB-UVB appears to be a very good option for treatment of AGP because of the good results obtained and patient satisfaction. Introduction 206 S. Karger AG, Basel Guttate psoriasis is a distinctive acute form of psoriasis, which is more frequent in children and young adults. It can be the first manifestation of psoriasis (acute guttate psoriasis, AGP) or an acute flare of a preexisting chronic plaque psoriasis []. The prevalence of psoriasis varies worldwide. The prevalence of psoriasis is 2% in Caucasians, and the prevalence of AGP is 4% of the clinical types of psoriasis [2]. AGP is strongly associated with preceding streptococcal infection which is found in the majority of the patients (clinical symptoms, positive serologies or cultures) [3]. It is accepted that AGP has a better prognosis than other forms of psoriasis; however, the eruption may cure spontaneously or progress into chronic plaque psoriasis or reoccur after some months or years []. The varied clinical picture of this well-defined clinical entity karger@karger.com S. Karger AG, Basel /6/ $39.50/0 Montserrat Fernández Guarino Avenida Ferrol 3, 3-2 ES Madrid (Spain) msn.com
2 Phototherapy with NB-UVB in AGP Patients included Older than 8 years With AGP (acute flare of their disease with plaques <3 cm) Without a history of a previous plaque psoriasis With more than 5% of BSA affected Primary outcome Number of patients achieving PASI90 Data collected Demographic data: age, sex, number of previous flares, age of onset of the psoriasis, history of pharyngitis or vaccination in the month prior to the flare, family history of psoriasis PASI before and after treatment with NB-UVB PASI 8 months after treatment Patient assessment, visual analog scale (0 0) Treatment protocol Phototherapy booth 33 nm UV 7002 (Waldmann, Villingen-Schwenningen, Germany) Three times a week Following patients skin phototype Each dose of irradiation was increased by 0% if there was no erythema Session 30 without PASI90 reached: suspended treatment Statistical analysis Fig.. Flowchart of the Material and Methods. BSA, body surface area. SPSS (IBM, New York, NY, USA) for Windows 2.0 Categorical data: 2 test Continuous data: Student t test p < 0.05 indicates statistical significance has led to a number of studies of possible triggers and its evolution over the years [4 6]. According to guidelines for the treatment of psoriasis, the first line of treatment for psoriasis involving more than 5% of body surface area is ultraviolet phototherapy (preferably narrow-band ultraviolet B, NB-UVB), either alone or in combination with methotrexate or acitretin [7 9]. AGP has been demonstrated to respond to NB- UVB better than other forms of psoriasis [0, ], but there is no consensus for the best treatment of AGP. There is little guidance in the literature as to how this distinctive form of psoriasis should be treated. Recently, a systematic review of intervention in AGP concluded that there is no firm evidence to make any recommendation for the routine treatment of AGP [2]. Most of the studies published about phototherapy in AGP are in children, and only a few of them used the PASI, which is the most studied and validated score to assess the severity of psoriasis, but it has not been assessed in AGP. The PASI was shown in a recent systematic review to be the best outcome measure, and so PASI75 and PASI90 are the most used scores in the recent studies about the treatment of psoriasis [7, 8, 2]. NB-UVB in Adult Guttate Psoriasis Dermatology 206;232:
3 n = 67 (adult patients with AGP) PASI: 8.5 ±5.03; sessions/doses: 9.9 ± 3.5/4 ± 0.5 mj/cm 2 ; PASI reduction: 88.2% CR or PASI90 = 52 (78%) PASI reduction = 96.5% PASI 7.9 ± 4.6; sessions/doses: 9.2 ± 8.5/4 ± 9. mj/cm 2 IR or not PASI90 = 0 (5%) PASI90 = 0% PASI reduction = 42% PASI: 0.4 ± 5.9; sessions/doses: 29.8 ±.8/2.5 ± 5.4 mj/cm 2 Lost to treatment n = 5 (7%) PASI:.4 ± 6.2; sessions/doses: 7.8 ± 4.7/5.6 ± 2.0 mj/cm 2 Color version available online CR or PASI90 after discontinuation = 46 (88%) PASI: 7.9 ± 3.93; sessions/doses: 8.7 ± 7.2/2.6 ± 8.6 mj/cm 2 Fig. 2. Results of the treatment (mean ± SD). Relapse n = 6 (2%) PASI: 8.25 ± 4.3; sessions/doses: 22.8 ± 7.9/20.3 ± 8.9 mj/cm 2 ; relapse: 3.2 months In this article we studied the results of phototherapy with NB-UVB in adult AGP, collected possible triggers, family history and clinical course. Finally, we assessed the patient satisfaction with treatment. Material and Methods For further details, see the supplementary materials (for all online suppl. material, see (Fig. ) [9, 3]. Results A total 67 adult patients with AGP were included in this study with an initial PASI of 8.55 (SD = 503) (see Fig. 2 ). Patients were treated with a mean of 9.9 (SD = 3.5) sessions and a mean dose of 4 mj/cm 2 (SD = 0.5) with a PASI reduction of 88%. A total of 52 out of 67 (78%) achieved complete response (CR) or PASI90, 0 out of 67 (5%) did not reach PASI90 (5%), and 5 out of 67 (7%) were lost to treatment. Among the 52 patients with CR or PASI90, a PASI reduction of 96.5% was obtained. Their initial PASI was 7.9 (SD = 4.6), and they received 9.2 (SD = 8.5) sessions with a cumulative dose of 4 mj/cm 2 (SD = 9.). A total of 46 (88%) of the patients with CR (46/52) maintained PASI90 during an 8-month follow-up period, and 6 of them (2%) lost PASI90 in 3.2 months. A total of 0 patients out of 67 (5%) did not reach PASI90 and obtained a PASI reduction of 42%. Nonresponder patients (incomplete response, IR) presented an initial PASI of 0.4 (SD = 5.9) and received 29.8 (SD =.77) sessions with a cumulative dose of 2.5 mj/cm 2 (SD = 5.4). Table summarizes the characteristics of the 2 groups of patients together with those patients lost to treatment: responders, nonresponders and lost to treatment. Patients who were lost to treatment were all women who had difficulties in coming to the hospital and did not complete the sessions for different reasons. One of them suffered a polymorphic solar eruption during treatment which had to be interrupted. However, most of the patients would repeat the treatment and assessed a global satisfaction of 7.4 out of 0. The differences in the variables measured between responders and nonresponders can be seen in the first 2 columns of Table. A summary of the statistical significance is shown in Table 2. Patients with CR had a mean age of onset of 26.7 years (range 8 58) with a mean of 4.82 years of evolution (range 0 7), and nonresponders had a mean age of 35.2 years at the onset (range 26 37) and a mean of 4.2 years of evolution (range 0 37). The difference in the age of onset and the years of evolution of the AGP previous to treatment was statistically significant (Student t test, p > 0.05, Table 2 ). Patients with CR were 22 males and 30 females (42/64%), 22 (42%) had had only flare and 30 (64%) 2 or more flares, and 24/52 (46%) had a family history of psoriasis. Patients with IR were 4 males and 6 females (40/60%), of them had had only flare (0%), and 2 had a family history of psoriasis (20%). No statistical differences were found between 628 Dermatology 206;232: Fernández-Guarino/Aboín-González/ Velázquez/Barchino/Cano/Lázaro
4 Table. Characteristics and assessment of the patients with respect to response to treatment CR/PASI90 (n = 52) IR/not PASI90 (n = 0) Lost to treatment (n = 5) Total (n = 67) Mean age of onset, years 26.7 (8 58) 34.9 (26 39) Age of treatment, years 33.9 (8 58) 35.2 (26 57) Male/female ratio 22/30 (42/64%) 4/6 (40/60%) 0/5 26/4 Time of evolution since the diagnosis, years 4.82 (0 7) 4.2 (0 37) Number of previous flares 2 >2 or always affected 22 (42%) 7 (4%) 23 (50%) (36%) 8 (%) 35 (53%) Pharyngitis or vaccination 36 (69%) 2 (20%) 3 (60%) 4 (6%) Family history Psoriasis Atopic dermatitis None 24 (46%) 3 (25%) 5 (29%) 8 (80%) 2 (20%) (50.7%) 7 (25.4%) 6 (23.9%) Always guttate psoriasis 52 (00%) 0/0 (00%) 5/5 (00%) 67 (00%) The best of the treatment results 46 fast 2 schedule 2 tanning no contraindications The worst of the treatment travel to hospital 42 nothing 7 erythema 2 multiple sessions results 8 pruritus control duration of response travel to hospital 8 relapse 2 results 3 pruritus control nothing travel to hospital 4 PSE results 57 (85%) move 54 (8%) Would you repeat the treatment? 5/52 (98%) 9/0 (90%) 4/5 (80%) 64 (96%) Global satisfaction score (range 0) PSE, polymorphic sun eruption. these 3 variables (sex, number of flares and family history, p > 0.05, χ 2 test, Table 2 ). A total of 36/52 (69%) patients with CR had a previous clinical history of pharyngitis, in contrast with only 2 out of 0 (20%) patients with IR; this difference was significant ( p < 0.05, χ 2 test). All of the patients with more than flare of AGP (43/67, 64%) had no changes in the form of psoriasis, and the clinical type was always guttate psoriasis. Patient satisfaction with the treatment was high with a mean of 8.75 out of 0 in all patients treated. CR patients had a higher score than IR patients, 9 versus 8.35, but the difference was not significant ( p < 0.05, Student t test). The best of the treatment features for most of the patients was the results (57/67, 85%), and the handicap was going to hospital (54/67, 8%). Nevertheless, most of the patients would repeat the treatment again (96%). This percentage was higher in patients with CR than in patients Table 2. Variables measured associated with response to NB-UVB in adult AGP Variables associated with poor response to NB-UVB (p < 0.05) Older age of onset of the psoriasis (p = 0.02) Longer time of evolution of the psoriasis prior to treatment (p = 0.0) PASI at baseline (p = 0.03) Variables not associated with poor response to NB-UVB (p > 0.05) Age of treatment with phototherapy (p = 0.75) Sex 2 (p = 0.27) Number of previous flares (p = 0.075) 2 Number of sessions needed to clearance (p = 0.0) Family history (p = 0.082) 2 No history of previous pharyngitis (p = 0.0) 2 Student t test. 2 Fisher test. Satisfaction with the treatment (p = 0.29) NB-UVB in Adult Guttate Psoriasis Dermatology 206;232:
5 with IR (98 vs. 90%), but it was also high in patients who were lost to treatment (80%) with no statistical difference ( p > 0.05, χ 2 test). Table 2 summarizes the statistical analysis of the data. The PASI previous to treatment was higher in patients with IR and was significant ( p < 0.05, Student t test). The number of sessions needed for the treatment and doses were lower in patients with CR ( p < 0.05, Student t test). Discussion This is the first study to assess with the PASI score the efficacy of phototherapy with NB-UVB in adult AGP. The effectiveness of the treatment was high, with 78% of the patients achieving PASI90 in a mean of 9.9 sessions with maintained response during 8 months without treatment. The patients treated had small plaques (<3 cm), which usually responded better to treatment with NB-UVB [0]. Other factors which influence the response to treatment are the degree of infiltration and location in the lower limbs [2, 4]. Nevertheless, it is surprising that there are few research studies published on the treatment of AGP [2], and all this evidence is supported by indirect conclusions of studies of psoriasis in general. Previous reports show that the efficacy of NB-UVB in psoriasis decreases when the plaques enlarge [4] and that plaque-type psoriasis requires a significant cumulative higher dose than guttate psoriasis [2]. It is difficult to compare our results with previous studies because they assessed different types of psoriasis together with a logical predominance of the plaque type. A recently published systematic review of 4 randomized controlled trials of phototherapy in psoriasis concluded that NB-UVB achieved PASI75 in 62% of the patients (range 45 79) with a total number of treatments from 4 to 34 sessions [7]. Two more studies investigated the combination of NB-UVB with topical treatments. NB-UVB and tazarotene obtained PASI75 in 0% of the patients [5] and with calcipotriol in 52% (in this study PASI75 is estimated in reference 7) [6]. Only 2 of the studies published in the literature reviewing NB-UVB in psoriasis assessed the size of the plaques [0, 7]. No concomitant treatment and no maintenance treatment were applied because of the good results (88% of CR in 8 months) although a recent study provides some evidence that maintenance with NB-UVB in plaque-type psoriasis may achieve a longer remission [8]. The very good response of adult AGP to NB-UVB in our study exceeds the results obtained with biologics in psoriasis [8] and suggested that NB-UVB should be the first line of treatment of AGP according to guidelines [7 9], but it also raised a number of variables to consider when AGP is evaluated together with plaquetype psoriasis. This was the reason for analyzing other data in our group of patients. Traditionally, patients with AGP have been divided into 2 groups in terms of prognosis, one showing CR and the other progressing into chronic plaque psoriasis without complete involution [20]. The exact percentage of AGP progressing into chronic plaques is not clear and varies in the studies from approximately 5 30% [4] to 68% with a follow-up period up to 0 years [5, 20 23]. In contrast, none of our patients with more than flare of psoriasis (n = 43) presented another clinical type of psoriasis despite being adults with a mean evolution of 6.62 years. AGP occurs more frequently in childhood, and a recent study of 34 patients seen in childhood with guttate psoriasis still had it in adulthood [4]. Maybe there are 2 forms of evolution of an AGP over the years as was proposed in previous works [5], but this does not necessarily involve a change of clinical type. The patients with CR and IR in our study showed some significant differences which could promote 2 different clinical courses, spontaneous healing or chronicity in outbreaks. Patients achieving CR or PASI90 had a mean PASI of 7.9 and needed 9.2 treatments while IR patients had a higher PASI and needed more sessions (0.4, 29.8 sessions, p < 0.05). A direct relationship between PASI and response to NB-UVB in AGP has not been shown in previous reports in the literature reviewed. The age of onset of the AGP and the time of evolution were significantly lower in patients with CR, but not the sex, the age receiving treatment or the number of previous flares. AGP in adults is more frequent with childhood onset but childhood onset does not seem an additional risk factor for higher severity [4, 5]. However, in our study patients with longer courses of AGP exhibited the worst response. In conclusion, good responders to NB-UVB with AGP are young patients with no long flares. In our study a mean of 50.7% of the patients had a firstor second-degree relative affected with psoriasis. This percentage was higher in patients with a bad response to treatment (80%) but it was not significant. In previous reports the family history of psoriasis was found in 33 49% of the patients [ 5, 2, 23, 24] ; AGP with a family history is prone to develop into chronic psoriasis and tends to have a poor prognosis. Curiously, 25% of the patients reported a family history of atopic dermatitis (25% in CR and 20% in IR, p > 0.05). A history of personal and fam- 630 Dermatology 206;232: Fernández-Guarino/Aboín-González/ Velázquez/Barchino/Cano/Lázaro
6 ily atopic dermatitis is presented in all types of psoriasis but it is more frequent in patients with AGP [23]. No history of previous vaccination was reported by any patient. A history of previous pharyngitis as a possible trigger of the flare was significantly ( p > 0.05) more frequent (69%) in patients achieving CR. This could be linked again with a better prognosis of patients with AGP in acute flares. Clinical studies suggest that a clear history of pharyngitis is presented in 9 82% and serological evidence in 54 93% [24 26]. A previous study found that patients with elevated ASLO titers had a better clinical course [5]. The time for considering an upper respiratory infection as a trigger is not clear but it is generally considered to be within a week to a month [25]. We did not routinely perform pharyngeal cultures or determine streptococcal antibodies in patients with AGP because most of them were cured or being treated when attending our outpatient clinic. Only patients with symptoms of pharyngitis were prescribed antibiotics as no benefits of adding antibiotics to the treatment of AGP without previous pharyngitis have been demonstrated [26]. Assessment of patient satisfaction has recently been incorporated in most of the studies about psoriasis treatment. Few previous phototherapy studies in psoriasis patients assess satisfaction or the PASI used. In a recent work, patient satisfaction with phototherapy and biologic treatment was high and comparable [27]. In our study patient global satisfaction was 8.35 out of 0, but it was higher in patients with CR, 9 out of 0. Most of the patients described the necessity to go to the hospital as the main disadvantage of phototherapy and the results as the main advantage of the treatment. Remarkably, 96% of all the patients treated would repeat the treatment again if necessary, even in the case of a bad response. There are no firm recommendations for the treatment of AGP. There are no studies published about PASI improvement or patient satisfaction measures. AGP is a particular entity, and the evidence of the percentage of patients developing chronic plaque psoriasis or patients with no more flares in years is not clear. However, the factors described as good for the course of AGP are also factors of good prognosis for treatment response to NB- UVB. In cases where AGP resolves spontaneously, maybe NB-UVB only accelerates the natural course of the disease and thus the impressive results of the treatment. As it is not possible to distinguish which patients will have one or other course of the disease, NB-UVB should be offered to all of them as a first line of treatment, but in the majority of patients the type of psoriasis remains the same. Patients treated with NB-UVB are very satisfied with the treatment. Acknowledgements We are grateful to Maria Sánchez Ronco for her help with the statistical study and Mery Harper for her editing and language assistance. Statement of Ethics All the patients signed informed consent for the treatment. Disclosure Statement The authors declare no conflicts of interest. There were no funding sources for this work. References Griffiths CE, Christophers E, Barker JN, et al: A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 56: Takahashi H, Nakamura K, Kaneko F, Nagakawa H, Lizuka H: Analysis of psoriasis patients registered with the Japanese society for psoriasis research from J Dermatol 20; 38: Nahary L, Tamarkin A, Kayam N, et al: An investigation of antistreptococcal antibody responses in gutatte psoriasis. Arch Dermatol Res 2008; 30: De Jager MEA, de Jong EMGJ, Meeuwis KAP, van de Kerkhof PCM, Seyger MMB: No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. J Eur Acad Dermatol 200; 24: Ko HC, Jwa SW, Song M, Kim MB, Kwon HS: Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol 200; 37: Manolache L, Petrescu-Sceleanu D, Benea V: Life events involvement in psoriasis onset/recurrence. Int J Dermatol 200; 49: Almutawa F, Alnomair N, Wang Y, Hamazavi I, Lim HW: Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol 203; 4: Chen X, Yang M, Cheng Y, Liu GJ, Zhang M: Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 203; 0: CD Carrascosa JM, López-Estebaranz JL, Carretero G, et al: Documento de consenso de fototerapia en la psoriasis del Grupo Español de Psoriasis: ultravioleta B de banda estrecha (UVBBE), láser y fuentes monocromáticas de excímeros y terapia fotodinámica. Actas Dermosifiliogr 20; 02: NB-UVB in Adult Guttate Psoriasis Dermatology 206;232:
7 0 Gokdemir G, Kivanç-Altunay I, Koslu A: Narrow-band phototherapy in patients with psoriasis: for which types of psoriasis is it more effective? J Dermatol 2005; 32: Carvalho R, Marques-Pinto G, Cardoso J: Psoriasis phototherapy experience from a Lisbon unit: a still valid therapeutic approach in the 2st century. Cutan Ocul Toxicol 203; 32: Chalmers RJ, O Sullivan T, Owen CM, Griffiths CE: Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000; 2: CD Pathirana D, Ormerod AD, Saiag P, et al: European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: Cameron H, Dawe RS, Yule S, et al: A randomized, observer-blinded trial of twice vs three times weekly narrow band ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002; 47: Behrens S, Grundmann-Kollmann M, Schiener R, et al: Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000; 42: Brands S, Brankman M, Bos J, et al: No additional effect of calcipotriol ointment on lowdose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol 999; 4: Kirke SM, Lowder S, Lloyd JJ, et al: A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol 2007; 27: Boztepe G, Karaduman A, Sahin S, Hayran M, Kolemen F: The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a randomized trial. Int J Dermatol 2006; 45: Puig L, Carrascosa JM, Carretero G, et al: Directrices basadas en la evidencia para el tratamiento de la psoriasis con fármacos biológicos 203. Actas Dermosifiliogr 203; 04: Martin BA, Chalmers RJ, Telfer NR: How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 996; 32: Ferrandiz C, Pujol RM, Garcia-Patos V, et al: Psoriasis of early and late onset: a clinical and epidemiologic study in Spain. J Am Acad Dermatol 2002; 46: Williams RC, McKenzie AW, Roger JH, Joysey VC: HL-A antigens in patients with guttate psoriasis. Br J Dermatol 976: 95: Mallbris L, Larsson P, Bergqvist S, et al: Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005; 24: Naldi L, Peli L, Parazzini F, Carrel CF: Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case control study. J Am Acad Dermatol 200; 44: Nahary L, Tamarkin A, Kayam N, et al: An investigation of antistreptococcal antibody responses in gutatte psoriasis. Arch Dermatol Res 2008; 30: Dogan B, Karabudak O, Harmanyeri Y: Antistreptococcal treatment of gutatte psoriasis: a controlled study. Int J Dermatol 2008; 47: Finch T, Shim TN, Roberts L, Johnson O: Treatment satisfaction among patients with moderate to severe psoriasis. J Clin Aesthet Dermatol 205; 8: Dermatology 206;232: Fernández-Guarino/Aboín-González/ Velázquez/Barchino/Cano/Lázaro
A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationPUVA: Shall we still use it for psoriasis in 2019?
PUVA: Shall we still use it for psoriasis in 2019? Ben Stoff MD, MA Associate Professor Emory Department of Dermatology Phototherapy: F003 March 1, 2019 DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationOriginal Policy Date
MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? CONCISE COMMUNICATION
CONCISE COMMUNICATION BJD British Journal of Dermatology Self-administration of hospital-based narrowband ultraviolet B (TL-01) phototherapy: a feasibility study in an outpatient setting S. Yule, S. Sanyal,
More informationCorporate Medical Policy
Corporate Medical Policy Ultraviolet Light Therapy in the Home Setting(UVB) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultraviolet_light_therapy_in_the_home 3/1996 11/2017 11/2018
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationPsoriasis in Jordan: a single center experience
Psoriasis in Jordan: a single center experience Shefaa Almashagbeh MD *, Deifallah Alsharari MD *, Hayat Khasawneh MD *, Diana Aljammal * MD, Hamzeh Al-housamieh MD* ABSTRACT Objectives: To evaluate the
More informationComparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris
IJMAMR 5 (2017) 1-6 ISSN 2053-1834 Comparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris Tran Hau Khang* and Le Huu Doanh National Hospital of Dermatology and Venereology,
More informationSTUDY. A Randomized Comparison of Methods of Selecting Narrowband UV-B Starting Dose to Treat Chronic Psoriasis
ONLINE FIRST STUDY A Randomized Comparison of Methods of Selecting Narrowband UV-B Starting Dose to Treat Chronic Psoriasis Robert S. Dawe, MBChB, MD, FRCP; Heather M. Cameron, MBChB, MRCGP; Susan Yule,
More informationEfficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis
Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis T. Shehzad ( Departments of Dermatology Naval Hospital PNS Shifa, Karachi. ) N. R. Dar ( Departments
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationAtopic dermatitis (AD) is a common chronic skin. Phototherapy in the management of atopic dermatitis: a systematic review.
Photodermatol Photoimmunol Photomed 2007; 23: 106 112 Blackwell Munksgaard r 2007 The Authors Journal compilation r 2007 Blackwell Munksgaard Review article Phototherapy in the management of atopic dermatitis:
More informationPhototherapy for Psoriasis. Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA
Phototherapy for Psoriasis Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA Disclosure Investigator: Clinuvel Estée Lauder Ferndale Incyte
More informationComparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report
SW Youn, et al Ann Dermatol Vol. 27, No. 2, 2015 http://dx.doi.org/10.5021/ad.2015.27.2.184 ORIGINAL ARTICLE Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists
More informationPredicting the Response to Phototherapy for Psoriasis Patients
A*STAR-NHG-NTU Skin Research Grant Joint Workshop 17 October 2015 Predicting the Response to Phototherapy for Psoriasis Patients Is it possible? Dr Eugene Tan Consultant Dermatologist National Skin Centre
More informationOriginal article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis
Original article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis Syed Shamsuddin, *Tahir Saeed Haroon Department of Dermatology, Bolan Medical Complex, Quetta * Department
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationLight Therapy for Psoriasis Protocol Medical Benefit Effective Date Next Review Date Preauthorization Review Dates Preauthorization is required.
Protocol Light Therapy for Psoriasis (20147) Medical Benefit Effective Date: 07/01/16 Next Review Date: 03/18 Preauthorization Yes Review Dates: 03/16, 03/17 Preauthorization is required. The following
More informationSummary. DOI /j x
PHOTOBIOLOGY DOI 10.1111/j.1365-2133.2005.06533.x Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis K. Köllner, M.B. Wimmershoff,
More informationMonth/Year of Review: January 2015 Date of Last Review: January 2010
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationSYSTEMIC THERAPY OF MODERATE AND SEVERE PSORIASIS WITH METHOTREXATE
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 SYSTEMIC THERAPY OF MODERATE AND SEVERE PSORIASIS WITH METHOTREXATE M. FRÎNCU 1 A. OANŢĂ 1 Abstract:
More informationNarrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right left comparative study
Photodermatol Photoimmunol Photomed 2005; 21: 281 286 Blackwell Munksgaard Copyright r Blackwell Munksgaard 2005 Narrow band UVB (311 nm), psoralen UVB (311 nm) and therapy in the treatment of early-stage
More informationEFFECTIVENESS AND SAFETY OF NARROW BAND ULTRAVIOLET B THERAPY IN CHRONIC PLAQUE PSORIASIS
ORIGINAL ARTICLE EFFECTIVENESS AND SAFETY OF NARROW BAND ULTRAVIOLET B THERAPY IN CHRONIC PLAQUE PSORIASIS 1 4 Mohammad Majid Paracha, Irfanullah, Zafar Ali, Said Amin ABSTRACT Objectives: To determine
More informationRelation between the Peripherofacial Psoriasis and Scalp Psoriasis
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 28, No. 4, 2016 http://dx.doi.org/10.5021/ad.2016.28.4.422 ORIGINAL ARTICLE Relation between the Peripherofacial Psoriasis and Scalp Psoriasis Kyung Ho
More informationThe reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment
Original papers The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment Agnieszka Bożek A F, Adam Reich A F Department
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service:
More informationNarrow-band UVB PHOTOTHERAPY for Skin Diseases
Narrow-band UVB PHOTOTHERAPY for Skin Diseases By Dr. Manal Bosseila Cairo University, Egypt HISTORICAL ASPECT In 1978: Irradiation cabin with broad band UVB tubes was introduced for psoriasis & uremic
More informationNational Managed Clinical Network For Phototherapy DOSIMETRY PROTOCOLS
National Managed Clinical Network For Phototherapy DOSIMETRY PROTOCOLS Photonet Dosimetry Protocols Revised March 2013 Review Date March 2015 1 MANAGED CLINICAL NETWORK SCOTLAND Photonet CONTENT DOSIMETRY
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is the Addition of a Topical Agent to
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service:
More information5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris
87 5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris Supported by the EDF/EADV/IPC Pathirana, D.; Ormerod, A. D.; Saiag, P.; Smith, C.; Spuls, P. I.; Nast, A.; Barker, J.; Bos, J.
More informationGuselkumab for treating moderate to severe plaque psoriasis [ID1075]
Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationBrodalumab for treating moderate to severe plaque psoriasis [ID878]
Brodalumab for treating moderate to severe plaque psoriasis [ID878] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationClinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441
Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the
More informationDuring the last 20 years, the number of topical
THERAPEUTICS FOR THE CLINICIAN Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel Compared With Tretinoin Microsphere 0.04% and 0.1% Jonathan S. Dosik, MD; Kenneth Homer, MS; Stéphanie Arsonnaud
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationVitiligo is an acquired cutaneous disorder of
Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo Lubomira Scherschun, MD, Jane J. Kim, MD, and Henry W. Lim, MD Detroit, Michigan Background: The treatment of vitiligo remains
More informationQuality of life in children with psoriasis
Quality of life in children with psoriasis Marieke Seyger Psychodermatologie: het kind centraal Vrijdag 23 januari 2015 AMC Amsterdam Disclosure Has received research grants from / was involved in clinical
More informationIt is estimated that about 26,000 new cases of
Focus on CME at Dalhousie University Set On Soothing Psoriasis A. H. Murray, MD, FRCP(C) Presented at the 76th Annual Dalhousie Refresher Course It is estimated that about 26,000 new cases of psoriasis
More informationTHE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationActa Medica Marisiensis 2018;64(1):17-21
Acta Medica Marisiensis 2018;64(1):17-21 DOI: 10.2478/amma-2018-0003 RESEARCH ARTICLE Clinical and Therapeutic Trial for the Efficacy of Narrow Band - UVB Phototherapy versus Systemic Therapy in Moderate
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationPsoriasis is a chronic, inflammatory, T-cell mediated
Narrowband UVB Treatment Increases Serum 25-Hydroxyvitamin D Levels in Patients With Chronic Plaque Psoriasis Seyamak Saleky, MD; Işıl Bulur, MD; Zeynep Nurhan Saraçoğlu, MD PRACTICE POINTS The 25-hydroxyvitamin
More informationScientific Report On PhotoTherapy
Scientific Report On PhotoTherapy What exactly is psoriasis? Psoriasis is an immune-mediated disease. This means that your immune system causes your skin cells to reproduce in 4 days instead of 30 days,
More informationEffects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study
Effects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study Peiyi Chen 1, Tiantian Xin 2* and Yingchun Zeng 3,4 1 School of Nursing, Guangzhou University of Chinese
More informationLight Therapy for Psoriasis. Description
Subject: Light Therapy for Psoriasis Page: 1 of 11 Last Review Status/Date: June 2015 Light Therapy for Psoriasis Description Light therapy for psoriasis includes both targeted phototherapy and photochemotherapy
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More informationPravit Asawanonda, MD, DSc, and Yaowalak Nateetongrungsak, MD Bangkok, Thailand
Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study Pravit Asawanonda, MD, DSc, and
More informationLaser, Light Therapy, and Cryotherapy for Acne Vulgaris Non-Pharmacologic Treatment of Rosacea
2.01.47 Light Therapy for Psoriasis Section 2.0 Medicine Subsection Effective Date October 31, 2014 Original Policy Date June 13, 2001 Next Review Date October 2015 Description Plaque psoriasis, also called
More information2 SYNOPSIS. Study code : MC 9308 FR.
MC9308 FR Study 19 December 2000 Page 15 of142 2 SYNOPSIS Study code : MC 9308 FR. Title: A comparative study of calcipotriol ointment in combination with narrow-band UVB (TL-01) phototherapy and placebo
More informationBioavailability 55% - 77%
Brand Name: Cosentyx Generic Name: secukinumab Manufacturer 1 : Novartis Pharmaceuticals Corporation Drug Class 2,3 : Antipsoriatic Agent, Interleukin-17A Receptor Antagonist Uses: Labeled Uses 1,2,3 :
More informationChildhood psoriasis: Analytic retrospective study in Saudi patients
Journal of the Saudi Society of Dermatology & Dermatologic Surgery (2011) 15, 57 61 King Saud University Journal of the Saudi Society of Dermatology & Dermatologic Surgery www.ksu.edu.sa www.jssdds.org
More informationAnn Dermatol Vol. 26, No. 1, 2014
Ann Dermatol Vol. 26, No. 1, 2014 http://dx.doi.org/10.5021/ad.2014.26.1.17 ORIGINAL ARTICLE Spectrophotometric Measurement of Minimal Erythema Dose Sites after Narrowband Ultraviolet B Phototesting: Clinical
More informationClinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17
Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationTherapeutic Management of Early Cutaneous Mycosis Fungoides
Therapeutic Management of Early Cutaneous Mycosis Fungoides L Frank Glass, MD Cutaneous Lymphoma Programs H Lee Moffitt Cancer Center and Research Institute George Washington University Dermatology and
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationMedical Policy. MP Light Therapy for Psoriasis
Medical Policy MP 2.01.47 BCBSA Ref. Policy: 2.01.47 Last Review: 12/27/2017 Effective Date: 12/27/2017 Section: Medicine Related Policies 2.01.44 Dermatologic Applications of Photodynamic Therapy 2.01.86
More informationCombination Topical PUVAsol with Methotrexate Versus Methotrexate in the Treatment of Palmoplantar Psoriasis Karn D, KC S
Combination Topical PUVAsol with Methotrexate Versus Methotrexate in the Treatment of Palmoplantar Psoriasis Karn D, KC S ABSTRACT Background Department of Dermatology Dhulikhel Hospital, Kathmandu University
More informationPrevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 29, No. 6, 2017 https://doi.org/10.5021/ad.2017.29.6.761 ORIGINAL ARTICLE Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using
More informationJosephine Mauskopf Miny Samuel Doreen McBride Usha G. Mallya Steven R. Feldman
PharmacoEconomics (2014) 32:395 409 DOI 10.1007/s40273-014-0130-5 SYSTEMATIC REVIEW Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review
More informationMaintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study
ORIGINAL ARTICLE Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study Marine Cavalié 1, Khaled Ezzedine 2, Eric Fontas 3, Henri Montaudié
More informationTopical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar
Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar Dr. Steven Feldman 1 Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands
More informationPsoriasis: Causes, Symptoms, And Treatment
Psoriasis: Causes, Symptoms, And Treatment We all know that a healthy immune system is good. But, do you know that an overactive immune system can cause certain conditions like Psoriasis? Read on to find
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More information308-nm excimer laser plus topical calcipotriol in the treatment of vitiligo; A single blind randomized clinical study
Original Article 308-nm excimer laser plus topical calcipotriol in the treatment of vitiligo; A single blind randomized clinical study Hassan Seirafi, MD 1 Maryam Daneshpazhouh, MD 1 Somayeh Khezri, MD
More informationCOMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW
COMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW Dr. Shweta Aryal *, Prof. Dr. Liu Jin Xian, Dr. Gong Shao Zhi and Dr. Jyoti Karki
More informationD E R M A T O L O G Y
We customize individual prescriptions for the specific needs of our patients. F E B R U A R Y 2 0 1 3 I N S I D E T H I S I S S U E : Psoriasis Vulgaris 2 Atopic Dermatitis 3 P R E S C R I P T I O N C
More informationCOST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS
COST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS Cheryl S. Hankin PhD 1 ; Steven R. Feldman, MD, PhD 2 ; Daniel Pearce, MD 2 1 BioMedEcon, San Jose, CA, USA; 2 Wake Forest University School
More informationANALYSIS OF IL17 AND IL17RA POLYMORPHISMS IN SPANISH PSORIASIS PATIENTS: ASSOCIATION WITH RISK FOR DISEASE.
ANALYSIS OF IL17 AND IL17RA POLYMORPHISMS IN SPANISH PSORIASIS PATIENTS: ASSOCIATION WITH RISK FOR DISEASE. Batalla A, Coto E*, González-Lara L, González- Fernández D, Maldonado-Seral C, García-García
More informationComparison of PUVA and UVB therapy in moderate plaque psoriasis. Arfan ul Bari, Nadia Iftikhar*, Simeen ber Rahman*
Comparison of PUVA and UVB therapy in moderate plaque psoriasis Arfan ul Bari et al. Arfan ul Bari, Nadia Iftikhar*, Simeen ber Rahman* Department of Dermatology, PAF Hospital, Sargodha. * Department of
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationUpdate on Daylight-PDT Practice in Medical and Cosmetic Clinic. Rolf-Markus Szeimies Recklinghausen, Germany
Update on Daylight-PDT Practice in Medical and Cosmetic Clinic Rolf-Markus Szeimies Recklinghausen, Germany DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Rolf-Markus Szeimies, MD PhD F024 Photodynamic Therapy
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationPsoriasis is a lifelong condition, with onset
THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie
More informationCOMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio
COMMON SKIN CONDITIONS IN PRIMARY CARE Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio DISCLOSURE The Speaker and members of the planning committee do not have a conflict of interest
More informationCombination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD
Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential
More informationUVB phototherapy and skin cancer risk: a review of the literature
Oxford, IJD International 0011-9059 Blackwell 45 UK Publishing Journal Ltd. Ltd, of Dermatology 2003 Review Lee, Koo, phototherapy and Berger and skin cancer risk UVB phototherapy and skin cancer risk:
More informationLiterature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ultraviolet Light Therapy for Skin Conditions Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ultraviolet Light Therapy for Skin Conditions Professional
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More information11 PROTOCOL NO. 11: Psoracomb (UVB TL01) protocol PROTOCOL NO. 12: MPD protocol 23 Appendix 25
Classification: Policy Lead Author: Tsui Ling Consultant Dermatologist, Clinical Additional author(s): N/A Authors Division: Dermatology Unique ID: GSCDerm02(13) Issue number: 3 Expiry Date: September
More informationPDT in Medical and Aesthetic Dermatology: An European Perspective. Rolf-Markus Szeimies Recklinghausen, Germany
PDT in Medical and Aesthetic Dermatology: An European Perspective Rolf-Markus Szeimies Recklinghausen, Germany DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Rolf-Markus Szeimies, MD PhD F066 Photodynamic Therapy
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationPHOTOTHERAPY. With narrowband UVB, the light tubes produce a narrow part of the UVB spectrum. Two wavelengths
Phototherapy (light therapy) refers to the use of ultraviolet (UV) light to treat moderate to severe eczema in children and adults. Phototherapy is a second-line treatment option that is available at specialist
More informationBJD. Summary. British Journal of Dermatology THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry
More informationRESEARCH INTRODUCTION. 79% (from 7.0 to 1.4) and 70% (from 7.0 to 2.1) for patients treated in an outpatient setting.
Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) Mayke B G Koek, research fellow, 1 Erik Buskens,
More informationSTUDY. The Development of Practice Guidelines for the Treatment of Severe Plaque Form Psoriasis
STUDY The Development of Practice Guidelines for the Treatment of Severe Plaque Form Psoriasis Phyllis I. Spuls, MD; Patrick M. M. Bossuyt, PhD; Jannes J. E. van Everdingen, MD, PhD; Leonard Witkamp, MD,
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationRisk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 30, No. 2, 2018 https://doi.org/10.5021/ad.2018.30.2.143 ORIGINAL ARTICLE Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis
More informationPsoriasis is a chronic, inflammatory, Prescribing in children
Psoriasis in children: current approaches to management Laura Proudfoot BSc, MRCP, Elisabeth Higgins MA, FRCP and Judy Davids RGN Our series Prescribing in children gives practical advice for successful
More informationThe utilization of phototherapy in the department of dermatology, Hospital Kuala Lumpur: A 5-year audit
ORIGINAL ARTICLE The utilization of phototherapy in the department of dermatology, Hospital Kuala Lumpur: A 5-year audit Vaani Valerie Visuvanathan, AdvMDerm 1, Min Moon Tang, AdvMDerm 2, Li Lian Tan,
More informationIs Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 3-2017 Is Apremilast (Otezla) Effective in
More informationProject manager. Dr. Nicola Zerbinati. Therapeutic protocols of monochromatic source 355 nm λ
Project manager Therapeutic protocols of monochromatic source 355 nm λ INTRODUCTION Artificial ultraviolet rays (UV) such as sunbeds, lamps, solar panels, are used both in the beauty and medical field,
More informationEfficacy of Topical Diphencyprone in the Treatment of Alopecia Areata
Original Article Efficacy of Topical Diphencyprone in the Treatment of Alopecia Areata Maryam Akhiani, MD Hasan Seyrafi, MD Farshad Farnaghi, MD Parastoo Banan, MD Vahideh Lajvardi, MD Department of Dermatology,
More information